The PARS2 antibody is a valuable tool for detecting the PARS2 protein, a mitochondrial aminoacyl-tRNA synthetase encoded by the *PARS2* gene. This enzyme catalyzes the attachment of proline to its cognate mitochondrial tRNA, a critical step in mitochondrial protein synthesis. As part of the family of aminoacyl-tRNA synthetases, PARS2 ensures translational fidelity within mitochondria, supporting oxidative phosphorylation and cellular energy production. Mutations in *PARS2* are linked to neurodevelopmental disorders, including autosomal recessive primary epilepsy with developmental delay, highlighting its role in neuronal function.
PARS2 antibodies are widely used in research to study mitochondrial dysfunction, particularly in contexts like epilepsy, neurodegenerative diseases, and metabolic disorders. They enable protein localization via immunofluorescence, quantification through Western blotting, and tissue-specific expression analysis using immunohistochemistry. Such studies have revealed PARS2's tissue-specific expression patterns, with high levels observed in metabolically active organs like the brain, heart, and liver.
The antibody also aids in exploring the molecular mechanisms underlying *PARS2*-related pathologies, such as impaired mitochondrial translation and subsequent respiratory chain deficiencies. By facilitating the detection of PARS2 in clinical and experimental models, these antibodies contribute to understanding disease pathogenesis and evaluating potential therapeutic strategies targeting mitochondrial protein synthesis pathways.